Elsevier

The Lancet

Volume 345, Issue 8949, 4 March 1995, Pages 578-579
The Lancet

Letters to the Editor
Trials of streptokinase in severe acute ischaemic stroke

https://doi.org/10.1016/S0140-6736(95)90484-0Get rights and content

References (5)

  • V. Benes et al.

    Effect on intra-arterial antifibrinolytic agents on autologous arterial emboli in the cerebral circulation of rabbits

    Stroke

    (1990)
  • E. Mori

    Safety and efficacy of fibrinolytic agents in acute ischaemic stroke

    Cerebrovasc Dis

    (1993)
There are more references available in the full text version of this article.

Cited by (187)

  • Intracerebral Hemorrhage

    2015, Stroke: Pathophysiology, Diagnosis, and Management
  • Intracerebral hemorrhage

    2011, Stroke: Pathophysiology, Diagnosis, and Management
  • Chapter 38 Intracerebral hemorrhage

    2008, Handbook of Clinical Neurology
    Citation Excerpt :

    Hemorrhage occurred in both lobar and deep hemispheric regions and was associated with a 45% mortality rate (Clark et al., 1997). Trials of intravenous streptokinase have shown significantly higher rates of ICH ranging from 6% to 21% with high mortality (Donnan et al., 1995; Multicentre Acute Stroke Trial—Italy [MAST‐I] Group, 1995; Multicenter Acute Stroke Trial—Europe Study Group, 1996). This may be due to an inappropriately high dose of drugs for cerebrovascular disease or the longer‐lasting fibrinolytic effect of streptokinase compared with tPA (Clark et al., 1997).

View all citing articles on Scopus
View full text